Overview

A Phase 1 Study Comparing AVP-786 With AVP-923

Status:
Completed

Trial end date:
2015-03-01

Target enrollment:

Participant gender:

Summary

To compare pharmacokinetics (PK) of AVP-786 (deuterated [d6] dextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) to AVP-923 (dextromethorphan hydrobromide [DM]/Q) at steady state.

Phase:

Phase 1

Details

Lead Sponsor:

Avanir Pharmaceuticals

Treatments:

Dextromethorphan
Quinidine
Quinidine gluconate